
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA …